Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Others

SELLAS Life Sciences (SLS) Cash from Investing Activities (2023)

SELLAS Life Sciences (SLS) has disclosed Cash from Investing Activities for 4 consecutive years, with -$3.0 million as the latest value for Q3 2023.

Quarterly Cash from Investing Activities changed N/A to -$3.0 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was -$3.0 million through Dec 2024, changed 0.0% year-over-year, with the annual reading at -$5.5 million for FY2023, 22.22% down from the prior year.
Cash from Investing Activities for Q3 2023 was -$3.0 million at SELLAS Life Sciences, down from $720000.0 in the prior quarter.
The five-year high for Cash from Investing Activities was -$3.0 million in Q3 2023, with the low at -$3.0 million in Q3 2023.